German benefit assessment hammers nail in Novartis' aliskiren coffin
This article was originally published in Scrip
Novartis' antihypertensive Rasilamlo (aliskiren plus amlopidine) offers no proven benefit over comparators, says Germany's Institute for Quality and Eficinecy in Healthcare, IWQiG. The conclusion comes as no surprise. In September the firm stopped marketing the drug in Germany because it did not have the necessary data to make a successful submission under the early benefit assessment.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.